Remez-Gabay Lital, Vdovich Olga, Akria Luiza, Kruzel-Davila Etty
Nephrology Laboratory, Research Institute, Galilee Medical Center, Nahariya, Israel.
Nephrology Department, Galilee Medical Center, Nahariya, Israel.
Front Immunol. 2025 Apr 10;16:1567999. doi: 10.3389/fimmu.2025.1567999. eCollection 2025.
Anti-platelet factor 4 (PF4) immunothrombosis is characterized by thrombocytopenia, thrombosis and enhanced NETosis and has been described in the absence of prior heparin exposure. This case report describes a patient with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who, while under immunosuppression, developed anti-PF4-mediated immunothrombosis, with NETosis significantly elevated compared to baseline markers observed during AAV. Treatment with intravenous immunoglobulin (IVIG) led to resolution of the syndrome, marked by a reduction in NETosis markers, restoration of platelet counts, and alleviation of the hypercoagulable state. We review the epidemiology, pathogenesis, clinical manifestations, and management strategies of thrombotic anti-PF4 immune disorders, highlighting the roles of AAV and dysregulated NETosis as key triggers. Early recognition of anti-PF4-mediated immunothrombosis without prior heparin exposure is critical, as prompt treatment with IVIG and direct thrombin inhibitors can significantly improve outcomes. This case underscores the interplay between NETosis, ANCA vasculitis, and thrombotic anti-PF4 immune disorders, emphasizing the therapeutic potential of IVIG in mitigating NETosis-related complications.
抗血小板因子4(PF4)免疫性血栓形成的特征为血小板减少、血栓形成和增强的中性粒细胞胞外陷阱形成(NETosis),且已在无肝素暴露史的情况下被描述。本病例报告描述了一名抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)患者,在免疫抑制治疗期间发生了抗PF4介导的免疫性血栓形成,与AAV期间观察到的基线标志物相比,NETosis显著升高。静脉注射免疫球蛋白(IVIG)治疗使该综合征得到缓解,表现为NETosis标志物减少、血小板计数恢复以及高凝状态缓解。我们回顾了血栓性抗PF4免疫疾病的流行病学、发病机制、临床表现和管理策略,强调了AAV和失调的NETosis作为关键触发因素的作用。在无肝素暴露史的情况下早期识别抗PF4介导的免疫性血栓形成至关重要,因为及时使用IVIG和直接凝血酶抑制剂治疗可显著改善预后。本病例强调了NETosis、ANCA血管炎和血栓性抗PF4免疫疾病之间的相互作用,强调了IVIG在减轻NETosis相关并发症方面的治疗潜力。